Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 145 of the 146 references it cites were found in a registry or an index.

Immune responses to AAV vectors: overcoming barriers to successful gene therapy

Open access

Abstract

Gene therapy products for the treatment of genetic diseases are currently in clinical trials, and one of these, an adeno-associated viral (AAV) product, has recently been licensed. AAV vectors have achieved positive results in a number of clinical and preclinical settings, including hematologic disorders such as the hemophilias, Gaucher disease, hemochromatosis, and the porphyrias. Because AAV vectors are administered directly to the patient, the likelihood of a host immune response is high, as shown by human studies. Preexisting and/or recall responses to the wild-type virus from which the vector is engineered, or to the transgene product itself, can interfere with therapeutic efficacy if not identified and managed optimally. Small-scale clinical studies have enabled investigators to dissect the immune responses to the AAV vector capsid and to the transgene product, and to develop strategies to manage these responses to achieve long-term expression of the therapeutic gene. However, a comprehensive understanding of the determinants of immunogenicity of AAV vectors, and of potential associated toxicities, is still lacking. Careful immunosurveillance conducted as part of ongoing clinical studies will provide the basis for understanding the intricacies of the immune response in AAV-mediated gene transfer, facilitating safe and effective therapies for genetic diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2013-01-306647

Cites

145 of 145 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 146 references

Research works printed but not linked: 2

  1. Stone, 2010, Directed evolution of adeno-associated virus variants that evade human neutralizing antibodies [abstract]., Mol Ther, 18, S3
  2. Hui, 2012, Characterization of AAV T cells epitopes presented by splenocytes from normal human donors [abstract]., Mol Ther, 20, S215

Cited by

See all 996

Metadata

Authors
Mingozzi, F., & High, K. A.
Affiliations
Children's Hospital of Philadelphia (US)
Venue
Blood
Published
2013-07-04
Volume
122
Issue
1
Pages
23-36
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W1994064996
Cited by
955
References
146
Citations by year
2026: 97 · 2025: 94 · 2024: 74 · 2023: 86 · 2022: 87 · 2021: 80 · 2020: 95 · 2019: 71 · 2018: 62 · 2017: 68 · 2016: 29 · 2015: 59 · 2014: 42 · 2013: 11
FWCI
5.77
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Howard Hughes Medical Institute
  • National Heart, Lung, and Blood Institute (P01HL64190, P01HL064190, P01HL078810)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
adeno-associated virus vectors, immune response to gene therapy, immunogenicity, pre-existing immunity, recall immune response, hematologic disorders, hemophilia, Gaucher disease, hemochromatosis, porphyria, gene therapy toxicity, long-term transgene expression
MeSH terms
Dependovirus, Antibodies, Viral, Genetic Vectors, Humans, Genetic Therapy, Genetic Diseases, Inborn

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immune responses to AAV vectors: overcoming barriers to successful gene therapy. https://app.cochat.ai/papers/10.1182/blood-2013-01-306647
The paper
Mingozzi, F., & High, K. A. (2013). Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood. https://doi.org/10.1182/blood-2013-01-306647

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.